



Transcription Factor E2F in Normal and Cancer Cells

Guest Editor:

Dr. Kiyoshi Ohtani

Department of Biomedical
Sciences, School of Biological
and Environmental Sciences,
Kwansei Gakuin University, 1
Gakuen Uegahara, Sanda 669-
1330, Hyogo, Japan

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

As the principal target of the tumor suppressor pRB, E2F plays crucial roles in many important biological processes such as cell proliferation, DNA repair, tumorigenesis, apoptosis, cellular senescence, tumor suppression, development, differentiation, metabolism, stemness, invasion, metastasis, angiogenesis and others. The main obstacles in the radical treatment of cancers are side effects caused by the damage to normal growing cells. To avoid these side effects, we have to specifically target cancer cells. In almost all cancers, the RB pathway is disabled due to oncogenic changes, and the E2F activity is enhanced. Hence, many of the biological processes mentioned above may be affected and may represent a unique feature of cancer cells, which can be utilized to specifically target cancer cells to avoid side effects.

This Special Issue aims to explore E2F-based changes in cancer cells and also in normal cells upon oncogenic changes, seeking new approaches to specifically target cancer cells. Original research articles and reviews are welcome.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[X@Biomol_MDPI](https://twitter.com/Biomol_MDPI)